Biden’s $300M Contracts to Reuters ‘Target Elon Musk’ as Federal Agencies Investigate His Companies: Report 
How to use an AI art detector 
Donald Trump to Allegedly ‘Waive Apple’s China Tariffs’ as He Aims to Stop Samsung From Dominating Global Market 
Dr. Joseph Mercola Debunks Common Weightlifting Myths: What You Really Need to Know for Effective Strength Training 
CNN's 'Historic Ratings Collapse' in 2024 Election Year Raises Industry Concerns 
Toyota and Ford’s ‘Staggering’ $1 Million Donations to Trump’s Inauguration Spark Intense Public Debate 
Elon Musk Tells Users to ‘Stop Using Hashtags’ on X as Platform Moves Away From Trends 
Honda and Nissan Ready to Kick Off Integration Talks to Counter Tesla and Chinese Auto Giants 
Samsung Plans Ultra-Thin Galaxy S25 Slim to Rival iPhone 17 Air in 2025 Flagship Battle 
Nintendo Switch 2 Dock Leak Hints at Faster Performance but 4K Output Reportedly Capped at 30 FPS 
BC.GAME Enters Online Poker Market with BCPoker Launch Featuring Three Classic Variants 
Elon Musk Sparks Outrage Claiming 'Newsrooms Illegal for Republicans' in Wake of Shocking Journalist Data 
Economic Indicators from Auction Trends: What Car Auctions Reveal About Consumer Confidence 
Honda and Nissan Push 2026 Merger as Ex-CEO Ghosn Criticizes Bold Move 
American Airlines to ‘End DEI Hiring Practices’ After Complaint Sparks Federal Intervention and Policy Review 
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
